Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(2.30)
# 2,566
Out of 4,902 analysts
506
Total ratings
38.48%
Success rate
-0.69%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
IRON Disc Medicine | Reiterates: Buy | $118 | $57.79 | +104.19% | 16 | Jul 3, 2025 | |
ARGX argenx SE | Reiterates: Buy | $720 | $572.71 | +25.72% | 39 | Jul 1, 2025 | |
CRNX Crinetics Pharmaceuticals | Reiterates: Buy | $81 | $33.02 | +145.31% | 24 | Jun 27, 2025 | |
ROIV Roivant Sciences | Reiterates: Buy | $18 | $11.65 | +54.57% | 20 | Jun 18, 2025 | |
SAGE Sage Therapeutics | Reiterates: Neutral | $12 | $9.14 | +31.29% | 23 | Jun 17, 2025 | |
CABA Cabaletta Bio | Reiterates: Buy | $25 | $1.68 | +1,388.10% | 26 | Jun 11, 2025 | |
PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $56.44 | +41.74% | 33 | Jun 3, 2025 | |
XENE Xenon Pharmaceuticals | Reiterates: Buy | $53 | $32.11 | +65.06% | 5 | May 13, 2025 | |
PRAX Praxis Precision Medicines | Reiterates: Buy | $105 | $54.94 | +91.12% | 23 | May 1, 2025 | |
CHRS Coherus Oncology | Reiterates: Buy | $7 | $0.90 | +681.42% | 25 | Apr 29, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $5.54 | +152.71% | 17 | Apr 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $17.05 | +99.41% | 16 | Apr 23, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $9.34 | +189.08% | 27 | Apr 10, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $15.48 | +22.74% | 4 | Apr 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.50 | +380.00% | 17 | Apr 1, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $4.86 | +270.37% | 14 | Mar 20, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $18.28 | +178.99% | 22 | Mar 19, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.71 | +952.63% | 7 | Mar 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 | $15.11 | +257.38% | 14 | Mar 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $20.04 | +184.43% | 26 | Mar 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $11.62 | +29.09% | 15 | Feb 27, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.99 | +151.26% | 14 | Feb 26, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $3 | $2.31 | +29.87% | 16 | Feb 18, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $29.36 | +56.68% | 23 | Feb 13, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.25 | +88.24% | 9 | Nov 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.78 | +46,113.09% | 8 | Oct 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.15 | +769.57% | 5 | Jun 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $146.88 | +23.91% | 4 | Feb 20, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.30 | +156.85% | 2 | Jan 23, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $29.73 | -39.46% | 3 | Aug 29, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $16.31 | -50.95% | 7 | Jun 11, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $22.28 | +133.39% | 2 | Jun 11, 2019 |
Disc Medicine
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $57.79
Upside: +104.19%
argenx SE
Jul 1, 2025
Reiterates: Buy
Price Target: $720
Current: $572.71
Upside: +25.72%
Crinetics Pharmaceuticals
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $33.02
Upside: +145.31%
Roivant Sciences
Jun 18, 2025
Reiterates: Buy
Price Target: $18
Current: $11.65
Upside: +54.57%
Sage Therapeutics
Jun 17, 2025
Reiterates: Neutral
Price Target: $12
Current: $9.14
Upside: +31.29%
Cabaletta Bio
Jun 11, 2025
Reiterates: Buy
Price Target: $25
Current: $1.68
Upside: +1,388.10%
Protagonist Therapeutics
Jun 3, 2025
Reiterates: Buy
Price Target: $80
Current: $56.44
Upside: +41.74%
Xenon Pharmaceuticals
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $32.11
Upside: +65.06%
Praxis Precision Medicines
May 1, 2025
Reiterates: Buy
Price Target: $105
Current: $54.94
Upside: +91.12%
Coherus Oncology
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $0.90
Upside: +681.42%
Apr 28, 2025
Reiterates: Buy
Price Target: $14
Current: $5.54
Upside: +152.71%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $17.05
Upside: +99.41%
Apr 10, 2025
Reiterates: Buy
Price Target: $27
Current: $9.34
Upside: +189.08%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $15.48
Upside: +22.74%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $2.50
Upside: +380.00%
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $4.86
Upside: +270.37%
Mar 19, 2025
Reiterates: Buy
Price Target: $51
Current: $18.28
Upside: +178.99%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.71
Upside: +952.63%
Mar 4, 2025
Reiterates: Buy
Price Target: $54
Current: $15.11
Upside: +257.38%
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $20.04
Upside: +184.43%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $11.62
Upside: +29.09%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.99
Upside: +151.26%
Feb 18, 2025
Maintains: Buy
Price Target: $30 → $3
Current: $2.31
Upside: +29.87%
Feb 13, 2025
Reiterates: Neutral
Price Target: $46
Current: $29.36
Upside: +56.68%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $4.25
Upside: +88.24%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.78
Upside: +46,113.09%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.15
Upside: +769.57%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $146.88
Upside: +23.91%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.30
Upside: +156.85%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $29.73
Upside: -39.46%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $16.31
Upside: -50.95%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $22.28
Upside: +133.39%